My Lab's core affiliation is with the Cancer Prevention and Control Program at FCCC. In addition, I hold an adjunct position in the Department of Radiation Oncology, am a member of the Cancer Epigenetics Institute within FCCC and maintain adjunct faculty roles at Drexel University School of Medicine, Temple University’s Lewis Katz School of Medicine, and its College of Public Health. 

My principal focus revolves around understanding how innate genetic variation in DNA repair can shape an individual's predisposition to cancer and influence the outcomes for patients undergoing DNA-damaging treatments, such as chemotherapy and radiation. As a trained molecular geneticist, I delve into studying polymorphisms or mutations that may compromise the efficiency of DNA damage response and repair. With this knowledge, our goal is to identify biomarkers that can predict cancer susceptibility and treatment outcomes. These potential biomarkers include unique genes, their polymorphisms, proteins, and other molecular signifiers that shed light on both cancer risks and patient outcomes. In my lab, we adopt a multi-disciplinary approach, harnessing techniques from molecular genetics, biochemistry, and cellular biology. We actively collaborate with a diverse group of professionals, including clinicians, epidemiologists, bioinformaticians, and computational biologists.